Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2566)

POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 HELD ON MONDAY, DECEMBER 22, 2025

The board of directors (the "**Board**") of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (the "**Company**") is pleased to announce the poll results of the second extraordinary general meeting of 2025 (the "**EGM**") held on Monday, December 22, 2025.

For details of the resolutions considered at the EGM, the shareholders of the Company (the "**Shareholders**") may refer to the notice of the EGM and the Company's circular both dated December 2, 2025 (the "**Circular**"). Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

CONVENING AND ATTENDANCE OF THE EGM

The EGM was held as an on-site meeting at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou, Zhejiang Province, PRC on Monday, December 22, 2025.

The EGM was convened by the Board and hosted by Mr. Fu Hang, the chairman of the Board. All the directors and supervisors of the Company attended the EGM, either in person or online.

The convention of the EGM was in compliance with the requirements of the applicable PRC laws and regulations, the Listing Rules, and the articles of association of the Company (the "**Articles of Association**"). All the proposed resolutions as set out in the notice of the EGM were tabled before the EGM for Shareholders' consideration and approval, and were put to vote by way of poll.

To the best knowledge of the Board, having made reasonable inquiries (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the EGM; (ii) no Shareholder has a material interest in the matters considered at the EGM and was required under the Listing Rules to abstain from voting at the EGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the EGM.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 245,398,800, including 136,302,015 Unlisted Shares and 109,096,785 H Shares. As at the date of the EGM, there were (i) no treasury Shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury Shares have been exercised at the EGM; and (ii) no Shares repurchased by the Company which are pending cancellation. The number of Shareholders and authorized proxies attended the EGM was ten. Shareholders and authorized proxies holding an aggregate of 133,458,837 Shares attended the EGM, representing approximately 54.38% of the total number of issued Shares with voting rights.

At the EGM, the following resolutions were considered and passed by registered poll and the poll results are set out as follows:

Ordinary Resolutions		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the grant of authorization to the Board and its delegated persons to handle matters related to the H Share Full Circulation.	133,458,837 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the proposed H Share Full Circulation.	133,458,837 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To consider and approve the resignation and proposed appointment of non-executive Director.	133,386,837 (99.95%)	72,000 (0.05%)	0 (0.00%)

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 3, such resolutions were duly passed as ordinary resolutions.

ELECTION OF MEMBERS OF THE FIRST SESSION OF THE BOARD

With regard to the ordinary resolution numbered 3 above, Ms. Yan Weiting (嚴瑋婷) ("**Ms. Yan**") has been elected as non-executive Director of the first session of the Board at the EGM. The term of office of Ms. Yan will continue until the expiration of the term of office of the first session of the Board, with effect from December 22, 2025. Pursuant to the Articles of Association, Ms. Yan is eligible for re-election upon the expiry of her term.

Pursuant to the requirements of Rule 13.51(2) of the Listing Rules, the details of the biographies of Ms. Yan and other information relating to her appointment are set out in the Circular. As of the date of this announcement, there is no change in such information.

SCRUTINEERS

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two Shareholders' representatives, and one supervisor of the Company served as the scrutineers of the EGM for scrutinizing and counting votes.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, PRC, December 22, 2025

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.